Diabetes mellitus is characterized by dysfunctional or destroyed β-cells in the pancreas, leading to insufficient insulin production and dysregulated blood sugars. In type 1 diabetes, autoimmune processes attack the β-cells, while in type 2 diabetes, chronic glucose lipotoxicity, inflammation, and insulin resistance contribute to β-cell stress and loss. Preserving β-cell mass and function is crucial to slow or reverse the progression of diabetes. Traditional treatments focus on insulin supplementation or improving insulin sensitivity, but new approaches attempt to protect and regenerate the β-cells themselves. In this context, interest is emerging in psilocybin, a psychedelic compound from “magic mushrooms”, due to its unique mechanisms of action. Psilocybin acts as an agonist on serotonin receptors (especially 5-HT2A and 5-HT2B), and these receptors are not only present in the brain but also on pancreatic β-cells, where they play a role in the regulation of insulin release. This review report examines the question of whether psilocybin a protective effect on the β-cells of the pancreas has. We discuss the available literature – from in vitro and animal studies to early clinical and epidemiological findings – with a focus on the preservation or restoration of β-cell function in type 1 and type 2 diabetes. Possible underlying mechanisms (serotonergic, anti-inflammatory, neurotrophic, and immunomodulatory) evaluated. Finally, we highlight key results, authors, dates, and limitations of current studies, and present a table of relevant studies.

Serotonin system and β-cell function

Research over the past decades has revealed the important role of serotonin (5-HT) in β-cell physiology. Serotonin is co-packaged with insulin in β-cell granules and acts as a local messenger within the islets. In the presence of glucose, serotonin released by β-cells binds to 5-HT receptors on those same cells and stimulates insulin secretion (glucose-induced insulin secretion). Moreover, serotonin can promote the growth and survival of β-cells. During pregnancy, for example, a strong increase in serotonin signaling occurs: the expression of the 5-HT2B receptor increases in mid-gestation, which induces an expansion of the β-cell population. Kim et al. (2010) demonstrated that serotonin plays a crucial role via 5-HT2B in the adaptation of β-cell mass to the increased insulin demand during pregnancy. Outside of pregnancy, serotonin also appears to contribute to β-cell maintenance; studies in animal models of insulin resistance report that serotonin supports both insulin secretion and β-cell proliferation.

Psilocybin is chemically similar to serotonin and mimics serotonin's effect by binding to serotonin receptors. In particular the 5-HT2A- and 5-HT2B receptors, The factors that activate psilocybin are relevant: 5-HT2A is broadly expressed (including centrally) and 5-HT2B is involved in β-cell proliferation, among other things. This overlap in mechanism of action forms the basis of the hypothesis that psilocybin can protect β-cells or stimulate regeneration, similar to the β-cell-supporting effects of serotonin itself. In addition, it is known that psilocybin is favorable safety profile has been shown in controlled settings and could therefore in principle be suitable for research into chronic indications. In the following, we discuss what is known to date about psilocybin's effects on β-cells from preclinical research.

Preclinical findings: psilocybin and β-cells

In vitro research

The first indications of a direct protective effect of psilocybin on β-cells come from a in vitro study by Gojani et al., published in Genes (2024). In this study, the INS-1 832/13 rat β-cell line was used – an immortalized insulinoma cell line widely used to model β-cell functions. The cells were pretreated with psilocybin (10 µM) for 2 hours, after which they were exposed to a high-glucose-high-lipid environment (25 mM glucose + saturated fatty acids) to mimic the diabetic environment of type 2 diabetes (gluco- and lipotoxicity). Similar conditions induce oxidative stress, inflammation and in β-cells. dedifferentiation (relapse to a less functional, progenitor-like state), as is often seen in chronic hyperglycemia.

Key results: β-cells that had been treated with psilocybin showed a significantly higher viability after 48 hours of glucosamine/fatty acid stress compared to untreated control cells. In other words, psilocybin prevented a portion of the β-cell death due to gluco-lipotoxic stress. Western blot analyses showed that psilocybin the activation of various apoptotic markers suppressed: thus it reduced the cleaving/activity of caspase-3/7 and the amount of pro-apoptotic proteins, while anti-apoptotic proteins were spared. At the level of signaling pathways, this was accompanied by a decrease in TXNIP and phospho-STAT1/STAT3 in the treated cells. TXNIP (thioredoxin-interacting protein) is a glucose-responsive protein that can promote β-cell apoptosis and inflammasome activation, and STAT1/3 are transcription factors involved in inflammatory and stress responses; the finding that psilocybin limited their activation indicates a anti-apoptotic and possible anti-inflammatory effect in β-cells. Figuratively speaking, psilocybin functioned as a shield for β-cells against a hostile metabolic environment.

Besides survival, Gojani looked et al. also to β-cell dedifferentiation. Under chronic stress, β-cells can lose their specialized insulin-producing identity and regressive genes (such as Pou5f1/Oct4, Nanog) express, which contributes to loss of function. Psilocybin treatment was found to affect these dedifferentiation-related genes: Pou5f1 and Nanog were less strongly upregulated in the psilocybin group under high glucose/fat conditions compared to untreated cells. This suggests that psilocybin may be the slows down the dedifferentiation process and thereby better preserves β-cell identity. However, the authors emphasize that this effect was subtle. In the discussion, they noted that psilocybin did not achieve full normalization of dedifferentiation markers – there were indications of favorable modulation, but some data even suggested a slight increase in dedifferentiation under certain conditions. The net result was therefore ambiguous: psilocybin clearly prevented β-cell loss through apoptosis, but had no strong restorative effect on the already impaired insulin function. or on complete dedifferentiation reversal. Indeed, it was noted that psilocybin-treated cells, despite their better survival, still impaired glucose-stimulated insulin secretion (GSIS) showed under the stress conditions – psilocybin acute insulin delivery did not recover noticeable. This is an important point: protection of β-cells does not automatically mean that they function optimally again, a nuance that follow-up studies need to explore in depth.

In summary, this delivered in vitro study preliminary evidence that psilocybin β-cells can protect against diabetes-related stress. The authors (EG Gojani, I. Kovalchuk et al., 2024) conclude that psilocybin “effectively counteracts the loss of β-cells due to high glucose/fat via reduction of apoptosis, and offers indications that it can inhibit β-cell dedifferentiation”. They call this a promising first step towards anti-diabetic interventions with psilocybin. Limits However, the artificial setting of the study is a rat insulinoma cell line. in vitro isolates β-cells from their natural environment (no immune system, no interaction with other cell types or circulatory factors). Moreover, this primarily concerned a model of type 2 diabetes (glucotoxicity); aspects relevant to type 1, such as autoimmune insulitis, were not included. The finding that GSIS did not improve suggests that psilocybin offers protection but not functionality adds under stress – something that is still important to address for clinical relevance.

Animal studies

In the field of in vivo We are still at the beginning of animal research. To date, there are no published animal studies. known that specifically evaluate the effect of psilocybin on pancreatic β-cells or diabetes progression. Kovalchuk et al. emphasized, based on their in vitro results, that further research in animal models of diabetes is necessary to confirm that the protective effects in vivo also perform.

One indirectly relevant animal study has been conducted into psilocybin's influence on metabolism and weight: a study in Translational Psychiatry (2022) investigated whether psilocybin could improve obesity-related parameters in mice. High doses of psilocybin or microdoses were administered to both diet-induced obese mice and genetic obesity models, and body weight, eating behavior, and combinations with GLP-1 agonists were examined. The results were largely negative: A single high dose of psilocybin had no significant effect on food intake or weight in obese mice, and repeated microdosing also did not change weight or appetite. Even the combination of psilocybin with a GLP-1 analog resulted in no additional weight loss. Although this study focused on obesity and did not determine β-cell function, it suggests that psilocybin on its own did not result in drastic metabolic improvements in mouse models. However, the authors noted that psychedelics have complex neurobiological effects that are difficult to translate to mice, and that human studies might show different outcomes. Important to note: in this mouse study, β-cells not directly examined (for example, no insulin secretion or β-cell mass determination was reported), so firm conclusions regarding β-cell preservation could not be drawn from this.

In summary, there is currently a gap in targeted in-vivo dataWe do not yet know whether psilocybin administration to diabetic animal models (for example, mice with type 1 autoimmunity or type 2 insulin resistance) improves β-cell survival, inhibits inulitis, or benefits glycemic control. This remains an important subject for future research.

Immunomodulatory and anti-inflammatory effects

A potential key to β-cell protection – particularly in type 1 diabetes and inflammatory stress in type 2 – lies in the immune system and inflammatory processes. Chronic inflammation contributes to β-cell apoptosis and dysfunction; in type 1, autoimmune T-cells destroy insulin-producing cells. In this regard, it is relevant that psychedelic substances, including psilocybin, strong immunomodulatory and anti-inflammatory effects can exercise. This is a relatively new insight from recent years of psychedelics research outside the purely neuropsychiatric context.

Classic psychedelics (LSD, DMT, psilocybin, etc.) grab you mechanistically via 5-HT2A receptors on immune signaling pathways. Activation of 5-HT2A on immune cells appears to be able to suppress the release of pro-inflammatory cytokines. For instance, it has been demonstrated in vitro and in animal models that the potent 5-HT2A agonist DOI (an LSD analogue) inhibits inflammation-induced production of tumor necrosis factor alpha (TNF-α) suppresses and reduces tissue damage caused by inflammation. Likewise, it showed Szabo et al. (2014) see that N,N-dimethyltryptamine (DMT) – another serotonergic psychedelic – caused strong anti-inflammatory effects in immune cells. For psilocybin Evidence itself comes from both human and preclinical research: a clinical pilot study in healthy volunteers found that single psilocybin administration acutely reduced TNF-α levels in the blood. This decrease in pro-inflammatory cytokine occurred rapidly after ingestion and points to a direct immunomodulatory effect of psilocybin in humans. At the same time, another inflammatory marker (e.g., IL-6) remained unchanged, suggesting that the effect is specific to certain cytokines. Interestingly, the immunological changes partly persistent appeared: there are indications that psilocybin can affect the immune profile not only acutely, but also in the longer term. reprogramming towards a less inflammation-promoting state.

Recent in vitro Data support these findings. Laabi et al. (preprint 2025) cultured microglia (immune cells of the brain) and exposed them to lipopolysaccharide (LPS) to induce an inflammatory response. Treatment with psilocybin or its active metabolite psilocin had two notable effects: (1) the production of TNF-α decreased significantly, and (2) the production of neurotrophic growth factor BDNF (Brain-Derived Neurotrophic Factor) increased. This action was dependent on serotonin receptor activation, as blockade of 5-HT2A/2B receptors reversed the effect. 5-HT7 and TrkB (the BDNF receptor) were also found to be involved. This result is important in the context of β-cells: TNF-α is also a mediator of inflammatory damage and insulitis in pancreatic tissue, so The ability of psilocybin to suppress TNF-α could contribute to the protection of β-cells during inflammatory processes (as in type 1 diabetes). At the same time, the increase in BDNF indicates that psilocybin a tissue repair promoting has a component, since BDNF is associated with cell survival and regeneration. Although microglia occur naturally in the brain, these findings are exemplary of a systemic immunomodulatory effectPsychedelics shift immune responses from a pro-inflammatory to a more regulated, possibly even tissue-repairing profile.

In a broader perspective, psychedelics are now being investigated as new anti-inflammatory therapies for chronic diseases. Nichols et al. (2022) wrote that psychedelics act via noveler pathways than classic immunosuppressants and show potential in inflammation-related disorders. Frontiers in Immunology published a review as early as 2015 (Szabo, 2015) which stated that “classic psychedelics have significant modulating effects on immune responses” and that 5-HT2A and sigma-1 receptors play a crucial role in immunological processes. Diseases mentioned in that context range from rheumatism and multiple sclerosis to depression and infections. Although diabetes was not explicitly mentioned there, type 1 diabetes is among the autoimmune diseases that can, in principle, benefit from interventions that influence the immune system. It is therefore not inconceivable that psilocybin-induced immunomodulation may weaken the autoimmune attack on β-cells in type 1 or temper the low-grade inflammation in type 2. This remains hypothetical for now, but constitutes an important subject for future research.

Neurogenic and neuroprotective effects

A striking feature of psilocybin (and related psychedelics) is their ability to neuroplasticity and neurogenesis to promote. In the brain, psilocybin has been shown to cause an increase in the density and size of dendritic spines within 24 hours of administration, indicating accelerated formation of new synaptic connections. Psilocybin also increases brain-derived growth factors such as BDNF, and induces a long-lasting rewiring of neural networks. Such properties make psilocybin attractive as a potential treatment for neurological disorders (such as depression, brain injury, or neurodegeneration) due to its recovery potential.

Although β-cells are endocrine cells and not neurons, the conceptual parallel is that psilocybin can support cell flexibility and repair. There are indications that psychedelics can promote tissue regeneration even outside the CNS. A very recent study suggested that psilocybin extends cell lifespan and can slow aging processes in mice. In a brain trauma model, psilocybin-assisted therapies are being investigated for their ability to stimulate neuroregeneration and reduce inflammation in the brain. Applied to the pancreas, one might speculate that such neurogenic mechanisms (such as increased expression of growth factors) might contribute to β-cell regeneration or transdifferentiation of progenitor cells into new β-cells. Bear in mind that the pancreas and brain share embryologically related developmental pathways, and some growth factors (e.g., BDNF, NGF) are also present in pancreatic tissue and influence islet cell survival. Psilocybin's stimulation of BDNF (seen in microglia in vitro) could therefore potentially β-cell protective be, since BDNF in the pancreas is associated with less apoptosis and better insulin release in certain settings. Furthermore, there is a possible neural pathway: the pancreas is under the control of the autonomic nervous system; improved neurogenic plasticity would the neuronal innervation of the islets and thereby could influence glucose regulation. This is largely speculative, as direct evidence for this is lacking, but it illustrates that psilocybin's effects can act broadly throughout the body, not just in the brain.

In sum, the “neurogenic” effects of psilocybin – such as the promotion of cell growth, survival factors, and synaptic plasticity – constitute an additional mechanism that may the resilience of β-cells increases against damage. It is conceivable that an environment with increased growth factors and reduced stress (such as psilocybin induces) helps β-cells to repair themselves or allows new β-cells to arise from remaining cells or stem cell reserves. These ideas still need to be scientifically tested in pancreas-specific experiments.

Burden of proof in humans

Currently there are no clinical studies published studies administering psilocybin to patients with diabetes to measure β-cell outcomes. All direct evidence is preclinical. Nevertheless, there are a few indirect human findings that support research into psilocybin in this context:

1. Epidemiological associations: a striking cross-sectional analysis (Simonsson et al., 2021) of the National Survey on Drug Use and Health (US) suggests that individuals who have ever used a classic psychedelic (such as psilocybin) have a lower risk of diabetes. In a population of >170,000 adults, lifetime psychedelic intake was associated with ~12% lower odds of diabetes compared with never-users. This coincided with ~23% lower odds of heart disease and a lower risk of being overweight. Naturally, this is a correlation; confounders (such as healthier lifestyles or dietary patterns among some psychedelic users) may contribute to the observed differences. The authors therefore caution that no direct preventive recommendations should be derived from this. Nevertheless, this association raises the hypothesis that Psychedelic use is associated with better cardiometabolic health, possibly via behavioral change or direct biological effects. They explicitly mention the anti-inflammatory and immunomodulatory properties of psychedelics as one of the possible explanations for better cardiometabolic outcomes. This epidemiological signal, although not proof of causality, prompts further research or controlled trials.

2. Psychological and behavioral effect: Although this falls outside the scope of cellular biology, it is known that psilocybin therapy for mental disorders often leads to improvements in well-being, behavioral change, and addiction reduction. For instance, psilocybin is being investigated as a treatment for alcohol and tobacco addiction, with indications that a few sessions initiate lasting behavioral changes. In the context of diabetes (particularly type 2), such an effect would be potentially valuable: if psilocybin helps someone improve diet and lifestyle, for example, through a change in mindset, this could indirectly relieve β-cell function. However, this is at most a secondary route; the current review focuses on direct biological effects.

3. Future clinical applications – microdosing: Igor Kovalchuk, senior author of the Genes (2024) study, speculated that microdosing psilocybin could become a treatment option for metabolic syndrome or prediabetes in the future. Microdosing involves taking very low, sub-perceptual doses repeatedly. Theoretically, this could keep the β-cells continuously in a more protected state without the strong psychoactive trip effects of full doses. To date, there are no clinical microdose trials specifically focused on metabolic outcomes, but this is an area being monitored.

At Table 1 The key studies and findings summarizing those to date provide insight into psilocybin's effect on β-cells and diabetes-related parameters are summarized below.

Table 1: Overview of relevant studies on psilocybin in the context of β-cells and diabetes. Findings encompass in vitro experiments (cell cultures), epidemiological correlations, and immunological in vitro studies providing mechanistic support. Collectively, these results suggest that psilocybin can protect β-cells against stress and potentially contribute to a more favorable environment for β-cell preservation via immunomodulation.

Conclusions and future outlook

Preliminary conclusion: Psilocybin shows potential in early studies as a protective factor for pancreatic β-cells. In cellular models of type 2 diabetes-like stress, psilocybin increased β-cell survival and reduced apoptosis, presumably by mimicking serotonin signals that normally protect β-cells. The compound also influenced genes involved in the loss of β-cell identity (dedifferentiation), suggesting that psilocybin the functional β-cell phenotype can retain longer. Moreover, the anti-inflammatory and immunomodulatory effects of psilocybin – such as the suppression of cytokines (TNF-α) and the activation of repair mechanisms (BDNF) – with mechanisms that could prove beneficial in both type 1 and type 2 diabetes (fewer autoimmune seizures, less chronic inflammation in the islets). Indirect evidence from large population studies further indicates that people who have used classic psychedelics surprisingly report diabetes or obesity less frequently, although this should be interpreted with caution.

Possible mechanisms: The protection of β-cells by psilocybin appears to be multifactorial. First, there is the serotonergic pathway: psilocybin activates 5-HT2A/2B receptors on β-cells, which appears to lead to a reduction in stress signals (TXNIP, STAT3) and apoptosis inhibition. This aligns with the physiological importance of serotonin for β-cells (stimulation of growth and insulin release). Secondly, there is a anti-inflammatory/immunomodulatory component: by tempering cytokine pathways and polarizing macrophages/microglia toward a less aggressive phenotype, psilocybin could indirectly protect β-cells from immunological attack or inflammatory damage. This is particularly relevant for type 1 diabetes, where an overshoot immune response destroys β-cells—a response that psychedelics might be able to partially “inhibit” (an idea that needs to be investigated in autoimmune diabetes models). Thirdly, play neurotrophic and neurogenic effects a role: psilocybin's stimulation of BDNF and synaptic plasticity points to a cellular environment that promotes repair and growth. Although not yet proven, it is conceivable that this extends to β-cells by promoting regeneration or adaptive capacity of the islets. Finally, a holistic factor to be mentioned: psilocybin can lead to an improved lifestyle (less stress, healthier eating, etc.) via the psyche and behavior, which in itself relieves β-cells. This behavioral influence is difficult to quantify but may be included in a therapeutic setting not be excluded as an additional benefit.

Limitations of current research: Despite the interesting findings, it must be emphasized that we are still at a very early stage. The crucial limitations are: (1) Lack of in-vivo confirmation: So far, the encouraging results have been found mainly in isolated cells. Whether the same effects occur in living organisms – with complex interactions, immune system, hormonal feedback – is unknown. For example, psilocybin may be metabolized differently in the body or the required concentrations may not be achievable without side effects. (2) Lack of clinical data: No clinical study in people with diabetes has administered psilocybin to measure β-cell parameters. Safety and effectiveness in this population are therefore unclear. We do know that psilocybin is relatively safe in psychiatric trials under controlled conditions, but extra vigilance is required in diabetics (e.g. for acute changes in blood glucose during the psychoactive experience). (3) Functional aspect: Even if psilocybin saves β-cells from apoptosis, it may not be sufficient to restore lost function. As seen in vitro, stressed β-cells continued to perform suboptimally in terms of insulin secretion despite psilocybin treatment. For clinical relevance, psilocybin will therefore likely need to be combined with other therapies that improve the metabolic environment (such as diet, GLP-1 analogs, etc.), so that the saved β-cells can effectively contribute to glucose regulation. (4) Dose and chronic use: Most current data come from single (high) doses. If psilocybin were to serve as a protective agent, microdosing or repeated low dosing might be necessary. However, the effects and safety of chronic microdosing have not yet been well studied; concerns exist regarding possible tachyphylaxis (decrease in effect upon repetition) or side effects such as 5-HT2B-mediated heart valve problems associated with long-term serotonin agonists (known from fenfluramine, among others).

Future prospects: The research field is open to various follow-up studies. Animal experiment It should be a priority to test psilocybin in models of both type 1 and type 2 diabetes. For example: can psilocybin (or psilocin) reduce the incidence of diabetes in NOD mice (autoimmune model)? Does psilocybin cause improved β-cell survival or glucose tolerance in an obesity or streptozotocin diabetes model? Such studies would also help to determine safe and effective dosing regimens. In vitro on human material: experiments with human islets (from donors) exposed to cytokines or high glucose would be very valuable to see whether the findings from the INS-1 cell line are translatable to primary human β-cells. On mechanistic In this area, further unraveling is needed: the role of specific receptors (5-HT2A vs 5-HT2B) can be investigated using selective antagonists. It is also interesting whether psilocybin can stimulate β-cell proliferation (via cell cycle analysis) – something that has not yet been examined in current studies, but for which the authors do make suggestions.

When preclinical results are sufficiently substantiated, a first clinical trial could be considered, possibly in high-risk prediabetics or recently diagnosed type 2 diabetes patients. In this regard, one could examine surrogate markers such as β-cell function (C-peptide secretion), insulin requirements, inflammatory markers, and safety/tolerance of (micro)doses of psilocybin. Naturally, this requires careful ethical consideration, given the psychoactive nature of psilocybin.

In conclusion do the current data offer a proof-of-concept that psilocybin has a protective effect on β-cells could have, primarily through anti-apoptotic and immunomodulatory actions. This opens a new research paradigm in which a substance from psychedelic medicine is repurposed for a metabolic disease. In view of the global diabetes epidemic (projections >780 million diabetics in 2045) and the need for β-cell-targeted therapies, this is an exciting development. At the same time, we must remain realistic: the findings are preliminary and have limitations, so psilocybin is still far from a proven diabetes remedy. However, it is remarkable that a substance primarily known for expanding consciousness now also offers hope in the laboratory for pancreatic cell preservation. The coming years will show whether this hope is justified through rigorous follow-up scientific research.

Important references: Gojani et al., Genes (2024); Kovalchuk interview in PsyPost (2024); Simonsson et al., Sci. Reports (2021); Szabo, Front. Immunol. (2015); Laabi et al. (SSRN preprint, 2025). These works and other cited studies form the basis of this overview and are listed as sources.